← Back
Data updated: Mar 10, 2026
GLAUKOS
OphthalmologyCardiovascularGastroenterology
GLAUKOS is a pharmaceutical company focused on Ophthalmology, Cardiovascular, Gastroenterology. Key products include EPIOXA HD/EPIOXA KIT.
2012
Since
5
Drugs
-
Trials
4
Approved (2yr)
Key Drugs
PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA
riboflavin 5'-phosphate sodium
4 indications · 2016
EPIOXA HD/EPIOXA KIT
riboflavin 5'-phosphate sodium
4 indications · 2025
IDOSE TR
travoprost
FP prostanoid receptor 2 indications · 2023
MITOSOL
mitomycin
1 indications · 2012
PHOTREXA VISCOUS IN DEXTRAN 20%
riboflavin 5'-phosphate
1 indications · 2016
Recent Activity
IDOSE TR 2026-01-27
Labeling
IDOSE TR 2026-01-27
Efficacy
EPIOXA HD/EPIOXA KIT 2025-10-17
Type 5 - New Formulation or New Manufacturer
PHOTREXA VISCOUS IN DEXTRAN 20% 2025-02-07
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Ophthalmology 54%
2 drugs Phase 3: 4 Phase 2: 5 Phase 1: 1
Cardiovascular 29%
1 drugs Phase 3: 3 Phase 2: 1 Phase 1: 1
Gastroenterology 17%
2 drugs
Pipeline Strength Pro
Loading...
Active (5)
Discontinued (0)
Company Info
- First Approval
- 2012-02-07
- Latest
- 2026-01-27
- Applications
- 4